Needham & Company Starts Aerie Pharma (AERI) at Buy

December 3, 2013 7:26 AM EST Send to a Friend
Get Alerts AERI Hot Sheet
Price: $25.33 +2.18%

Rating Summary:
    4 Buy, 0 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 29 | Down: 44 | New: 4
Trade AERI Now!
Join SI Premium – FREE
Needham & Company initiates coverage on Aerie Pharma (NASDAQ: AERI) with a Buy. PT $18.00.

"Aerie's product candidates include the phase 3-ready AR-13324, which represents the first potential novel mechanism of action for glaucoma in over 20 years, and PG324, a triple-action fixed-dose combination of AR-13324 and the market-leading PGA latanaprost," analyst Elliot Wilbur states. "These product candidates will target the entire spectrum of current glaucoma pharmacotherapy, a ~$2B U.S. market opportunity, and in our view could potentially emerge as a best-in-class treatment options given MOA novelty and triplicate mechanisms."

For an analyst ratings summary and ratings history on Aerie Pharma click here. For more ratings news on Aerie Pharma click here.

Shares of Aerie Pharma closed at $11.49 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, New Coverage

Related Entities

Needham & Company

Add Your Comment